Overview

* Akero Q2 net loss just shy of analyst expectations, per LSEG data

* Operating income beats estimates, reflecting controlled expenses, per LSEG data

Outlook

* Akero's cash reserves expected to fund operations into 2028

Result Drivers

* R&D EXPENSES - R&D costs increase due to ongoing clinical studies and manufacture of clinical supplies

* HIGHER COSTS - General costs increase lifting total operating expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Miss -$70.50 -$70.10

Income mln mln (5

Analysts

)

Q2 In line -$80.87 -$80.90

Operatin mln mln (5

g Income Analysts

)

Q2 Basic -$0.86

EPS

Q2 $80.87

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Akero Therapeutics Inc ( AKRO ) is $75.00, about 32.7% above its August 7 closing price of $50.45

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)